A B S T R A C T The purpose of the present experiments was to evaluate the role of circulating antibodies in the rejection of human renal allografts and to study the apparent target(s) for antibody binding. Eluates obtained from surgical biopsy and nephrectomy specimens of rejecting, cadaveric human renal allografts were tested for antibodies directed to structural antigens of normal kidney and for cytotoxic antibody activity against mononuclear cell populations. By indirect immunofluorescence 23 of 35 eluates contained immunoglobulin that bound to normal kidney. Staining was in smooth muscle only in 10 patients, in smooth muscle and other structures such as tubular basement membranes, proximal cells, or brush border in 9 patients, and in structures other than smooth muscle in 4 patients. All 16 INTRODUCTION Although participation of antibodies in the destruction of initial renal allografts in some experimental models is well demonstrated (1, 2) , the importance of antibodies in human renal allograft rejection has not been defined clearly (2) . They are thought to play a pivotal role in hyperacute rejection, associated with recipient presensitization and demonstrable reactivity with donor cells (3) (4) (5) . Moreover, their participation has been implicated in the development ofvascular lesions conspicuous in later rejections (6, 7) . Data establishing the relationship of circulating antibodies to graft fate in man are largely circumstantial, and include disappearance from circulation of preexisting antibodies when graft is placed, the appearance or rise in titer of antibodies after graft removal, development of rheumatoid factor and heterophile antibodies (8, 9) and deposition of immunoglobulin in vascular lesions, glomeruli, and tubulo-interstitial areas (7, 10) .
Stronger evidence has been adduced by analysis of eluates from renal allografts at nephrectomy or autopsy (11) (12) (13) (14) (15) (16) (17) (18) . Nevertheless, results have not been consistently positive for evidence of antibodies bound to grafts, and no studies of specificities of these eluates toward intrarenal structures have been reported. Antiglomerular basement membrane (GBM)1 anti-bodies have been eluted from allografts placed into patients with circulating GBM antibodies (19) (20) (21) (22) . The frequency of anti-TBM antibodies has not been studied, and there has been no systematic investigation searching for other structurally-specific antibodies in a group of rejecting (rejected) renal allografts.
The present studies of eluates from cadaveric renal allografts with marked deterioration of renal function or irreversible clinical rejection were undertaken for three purposes: (a) to determine the presence of antitissue antibodies in eluates from such grafts; (b) to characterize apparent antitissue antibodies for structural and organ specificity; and (c) to test these eluates concomitantly for their content of cytotoxic antibodies to different mononuclear cell populations (T cell, B cell, and monocytes).
Our results indicate that all eluates from rejecting cadaveric human renal allografts tested contained antibodies cytotoxic to allogeneic mononuclear cell populations. In addition, most contained antibodies with apparent specificity for structural antigens of normal, human kidney; some of these could be absorbed with peripheral blood buffy coat, platelets, and/or B cell-rich preparations. However, several ofthe eluates tested contained substantial concentrations of antibodies which appear to bind only to kidney. Absorption experiments and paired label, in vivo, fixation studies in rats indicated that these antibodies against specific kidney structures are a population of antibodies distinct and separable from the antibodies cytotoxic for defined mononuclear cell populations.
METHODS
Kidney specimens were obtained from cadaveric allografts placed into 35 recipients (group I). The specimens investigated included 17 surgical biopsies obtained from grafts showing serious deterioration of function and 25 nephrectomies obtained after irreversible rejection. All patients were still on standard immunosuppression at the time of biopsy or nephrectomy. No patients had received antilymphocyte globulin. No instances of "hyperacute" rejection are included and neither are any apparent cases of technical failure, tubular necrosis, etc. As controls, native kidneys were obtained by nephrectomy from 11 patients anticipating renal allografts (group II); 3 of the 11 later had allograft nephrectomy and are included in group I. These 11 patients had: glomerulonephritis (seven cases), focal sclerosing glomerulopathy, interstitial nephritis, nephrosclerosis, and reflux nephropathy (one case each); 9/11 had glomerular Ig deposits. None of the tissues tested were from patients with GBM antibody-mediated disease as inferred from direct IF, and tests of sera and eluates for GBM antibodies. One eluate of group II was known to contain antibodies specific for vascular smooth muscle.
Antibodies. Antisera to human immunoglobulins were made in rabbits using fractions of normal human serum or myeloma proteins as described previously (23) . Antisera to human renal tubular antigen and Tamm-Horsfall protein used as localization markers for tissue studies were made similarly, using antigens isolated as described by Edgington and associates (24) (27) ; counting was done in a well detector with thallium-activated crystal.
Anti-GBM antibodies. Anti-GBM antibodies were assayed in serum and eluates by indirect IF and radioassay (28) .
IF. Direct IF tests oftissue were done using incident-light fluorescence microscopy and conventional controls (23, 28) . For indirect IF using sera and eluates, samples were tested at known Ig concentrations. Cryostat sections were treated as described (28) To determine organ specificity, binding to nonrenal, human tissues was investigated. Eluates were incubated with sections of human tissues obtained freshly from surgical biopsy and/or autopsy including: heart, thyroid, lung, liver, spleen, testicle, skeletal muscle, adrenal, pancreas, stomach, gut, and lymph node. The IF staining technique was the same as that used with kidney sections.
A number of eluates known to bind to NHK were absorbed with either pooled whole human leukocytes (buffy coat), pooled, washed human platelets, or cultured human B cells. For absorption the eluates were incubated with an equal volume of packed cells, at room temperature for 1 h. After removal ofthe cells by centrifugation the eluates were concentrated back to their original volume before testing.
Paired label, in vivo binding studies ofradiolabeled eluates. Test eluates were radiolabeled with 125I or 131I, dialyzed free of inorganic iodine, and concentrated by diafiltration. Control proteins (either acid-citrate treated human FIl fraction or an apparently inert transplant eluate) were labeled with the alternate isotope, and prepared similarly to the test eluates. Approximately equal amounts of labeled test eluate and control protein were mixed and injected simultaneously (1-10 x 106 dpm of each) by tail vein into two lightly anesthetized SpragueDawley rats. Rats were treated with saturated solution of potassium iodide in drinking water, housed in metabolism cages, and killed after 72 h. At sacrifice the carcasses were perfused with saline and excised organs counted (liver, spleen, kidneys, skeletal muscle): kidneys were homogenized in a mechanical blendor, debris washed with phosphate-buffered saline; and the pellet after centrifugation at 4,000 g for 30 min was counted. The results were expressed as percent kidneyfixing antibody (KFab), which refers to the radioactivity fixed to the washed, particulate kidney debris, and is calculated as described by Lerner and Dixon (29) : KFab = counts per minute cpm kidney-fixed 125I-(blood 1251 x kidney 131I/blood 1311) cpm 1251 protein injected. Nine different transplant eluates were studied. Three eluates of native kidneys known to contain anti-GBM antibody were used as positive controls.
Cell preparations for cytotoxicity tests. Venous blood obtained from normal volunteer donors, members of the tissue typing laboratory reference panel, was anticoagulated with preservative-free heparin and the mononuclear cells were isolated on Ficoll-Hypaque (30) . After centrifugation at 400 g for 30 min at room temperature the mononuclear cells obtained from the interf;ace were washed once with RPMI 1640 medium containing 20% pooled human serum and suspended in the same.
Monocytes were isolated by adherence. For this, 20-30 x 106 mononuclear cells were cultured in 25 ml of medium in a 10-cm Diam dish at 37°C in a humid atmosphere containing 5% C02, 95% air. After about 2 h the nonadherent cells were removed by washing with culture medium, checking for completeness of their removal with an inverted phase microscope. It usually required five or six washes of 8-10 ml each for removal of lymphocytes. The adherent cells were then released from the dish by gently scraping the surface with a sterile rubber policeman. The cells were collected in a conical centrifuge tube containing RPMI 1640 with 20% pooled human serum and washed once. The resulting cell preparations were usually 75-95% viable. About 80% of the cells showed characteristics of monocytes upon staining with euchrysine and ingested latex particles.
B lymphocytes were obtained from the nonadherent cells by removal of T lymphocytes with neuraminidase-treated sheep erythrocytes: nonadherent lymphocytes were mixed with an equal volume of 2% neuraminidase-treated sheep erythrocytes (31) , incubated at 37°C for 15 min in a water bath with shaking, underlayered with Ficoll-Hypaque solution and refrigerated at 4°C for 30 min to allow the formation of rosettes. The preparations were then centrifuged at 400 g for 30 min and the B lymphocytes removed from interface were washed once and adjusted to 3 x 106 per ml. The B lymphocyte preparations usually contained <5% rosette-forming cells. Less than 10% reacted with a rabbit anti-human T cell serum; 70-95% were killed by a rabbit anti-human Ia serum.
T lymphocytes were prepared from the sheep cell rosettes by hypotonic lysis. Having discarded the supernatant fluid, the erythrocyte pellets containing the T lymphocytes were suspended in 1-2 ml ofTris-ammonium chloride solution (32) and incubated at 37°C for 10 min. The tubes were filled with saline solution and the T lymphocyte recovered by centrifugation. T lymphocyte preparations usually showed < 10% killing with a rabbit anti-human Ia serum and 80-85% were killed by a rabbit anti-human T cell serum.
Cytotoxicity tests. Cytotoxicity tests were performed using the Standard National Institutes of Health procedure for microcytotoxicity (33) . 16 different allograft eluates, selected because of the differing specificities they had in IF binding assays and sufficient eluate was available were tested. In these tests we used 2,000 T cells, and 3,000 B cells or monocytes and 0.001 ml of eluate or serum. The T cell preparations were incubated for 30 min with eluate or serum and 60 min with rabbit complement, both at room temperature. The B cell and monocyte cytotoxicity tests were incubated at 20°C for 60 min with eluate or serum and for an additional 120 min after addition of rabbit complement; rabbit complement was pretested to insure potency and lack of toxicity to human lymphocytes and monocytes. After the final incubation the reaction droplets were stained with eosin and fixed with formalin. (9 patients) , and (c) binding to structures other than vascular smooth muscle only (4 patients). In contrast, only 1 of 11 eluates from native, diseased kidneys (group II) contained antibodies specific for vascular smooth muscle. The other 10 eluates from native kidneys were negative. Moreover, all 11 were negative against all other NHK target sites. In three patients eluates from native kidneys were negative for smooth muscle antibodies, whereas their allografts contained them.
Quantitation of antibodies against specific kidney structures. Sera drawn from 18 patients at time of graft nephrectomy were tested along with their graft eluates. Serum from five patients contained antibodies with specificities similar to their graft eluates and eluates/serum ratios could be estimated: titration results of serum and eluate suggested preferential uptake of structurally-specific antibody by allografts in four ofthe five (eluates [11] [12] [13] [14] . Eluates from 14 patients contained antibodies not found in their serum. Titration of all eluates to the minimal Ig concentration at which specific staining could be seen confidently showed it to vary from 2.7 to 670,g/ml (median 62 ,ug/ml); in 14 of the 25 eluates tested binding was observed at Ig concentrations < 100 ,ug/ml (11 < 50 ,ug/ml) indicating that major amounts of structurally specific antibodies were present. IgG titers were not significantly different than FII fraction of human protein titers. Binding to nonrenal, human tissue sections. 10 eluates were tested. Eluates which contained antibodies to vascular smooth muscle of homologous kidney bound also to smooth muscle of stomach and gut, and to cardiac but not skeletal muscle. On the other hand, eluates containing antibodies to tubule cells and TBM did not stain other tissues, with one exception: Ig in one eluate bound also to pancreatic duct cells (not muscle cells). The single native kidney eluate with smooth muscle antibodies bound only to vascular smooth muscle, and did not cross-react with visceral smooth, cardiac, or skeletal muscle.
Absorption experiments. Whole buffy coat, pooled platelet concentrates, and pooled, cultured B-cell concentrates were equally effective in absorption of antibodies with apparent specificity for smooth muscle cells of homologous kidney and endothelium. However, none of these cell preparations diminished or eliminated binding to other structural antigens such as tubule cells, brush border, or TBM (Table II) . Paired label, in vivo studies of radiolabeled eluates. Nine allograft eluates were tested: two showed clear binding to renal tissue in excess of 1% (eluates 15 and 17, Table III ). Precipitation of immunoglobulin from the eluates before injection diminished renal binding substantially, but absorption of eluates with pooled human platelets and B-cell rich concentrates did not alter binding. Positive-control eluates used in these studies were three different native kidney eluates from patients with anti-GBM antibody-mediated disease; they had binding of 0.8-4.4% to renal sediment. Two other transplant eluates (eluates 11 and 22) showed smaller binding of uncertain significance.
Cytotoxic antibody reactivity. All eluates tested had cytotoxic reactivity toward one or more cell populations. In general, those eluates (eluates 4, 5, 12, 14, 20, 27 ) that contained antibodies reactive with T cells also were cytotoxic to B cells, but seldom with a predominantly monocyte-enriched cell population (Table IV) , K and tended to be more reactive. In contrast, those eluates essentially unreactive with T cells tended to be as reactive with monocytes as with B cell preparations. Cytotoxic antibodies against the B cell-enriched preparations coexisted with structural antibodies of all specificities, particularly smooth muscle antibodies. Serum from nine patients taken at the time of nephrectomy were tested also and the specificities differed from the eluates in seven (Table IV) rejected) cardaveric human renal allografts: cytotoxic antibodies to mononuclear cells and antibodies with specificity for structural kidney antigens demonstrable by immunofluorescence. Cytotoxic antibodies against isolated mononuclear cells were detected in every eluate tested. Specificities of the eluted antibodies often differed substantially and unpredictably from serum antibodies. Presumably eluates reflect a subset of antibodies that bound to donor kidney over a period oftime, whereas serum contains antibodies that did not bind to donor kidney and only those present at the time the sample was obtained. Thus, differences in the reactions of eluates and serum samples are not surprising.
In two thirds of eluates (23/35) antibodies to structural kidney antigens were detected by immunofluorescence; most common were antibodies to smooth muscle (19 of 23 eluates). These antibodies bound to vascular smooth muscle on homologous kidney sections, but reacted also with smooth muscle of other organs, binding to stomach, gut, and heart, but not to skeletal muscle. Thus, they were not organ-specific. Additionally, these antismooth muscle antibodies were absorbed by viable (38) . (3) The immune response, involving production of cytotoxic antibodies towards various cell populations and organ-specific, antistructural antibodies, may be more characteristic of the repertoire of available responses ofthe host than due to specific antigenic challenge.
The frequency ofstructurally-specific antibodies participating in pathophysiologic events characterized clinically as allograft "rejection" cannot be estimated accurately from our data for two principal reasons: (a) our observations derive from analyses of organs whose deterioration was sufficiently serious and sustained that biopsy or nephrectomy was done; (b) our data are derived from cadaveric grafts. The extent to which similar mechanisms participate in living, related-donor graft injury is not clear.
These observations are important in several regards.
First, cytotoxic antibodies were eluted successfully in every instance in this series ofrejecting renal allografts.
Moreover, two thirds of the eluates contained antibodies apparently reactive against smooth muscle of vascular walls, and some with endothelium, suggesting the involvement of humorl antibody in vascular lesions observed in renal allografts. Additionally, the eluates contained a variety of structurally-specific antibodies. Although TBM antibodies have been reported before in renal allografts recipients (20, 22, 34) , in the present series 22% of the eluates with antitissue antibodies contained TBM antibodies alone or in association with other structural specificities -a surprising frequency. Antibodies with apparent specificity for smooth muscle were detected in seven eluates, although no vascular Ig was detected by direct IF examination of the same kidneys. This disparity may be due to the segmental variation of pathologic processes which characterizes modified graft rejections. Another possibility is that elution, concentrating available antibodies into a small volume for testing, enhanced the likelihood of their detection. Mean minimal Ig concentrations at which smooth muscle antibodies were detected was 127,ug/ml (median concentration 71 ug/ml) in eluates from kidneys where direct IF was positive and 299 ,ug/ml (median concentration 136,ug/ml) in eluates from IF negative kidneys, suggesting that lesser amounts of smooth muscle antibody were present in the latter eluates. On the other hand, vascular Ig deposits were seen by direct IF without smooth muscle or endothelial antibodies in eluates in five cases. Similar vascular Ig deposits have been seen in renal biopsies from patients with arterial hypertension, where they have been attributed to insudation by passive forces or nonspecific vascular injury and not to immunological mechanisms.
There has not been any previous report of allografts with specific uptake of antiproximal cell antibodies, although an instance with Fanconi syndrome may have occurred in native kidney disease (38 However, since both cells also appear to have HLA-DR antigens, the specificity of the monocyte cytotoxic antibodies observed in the present study is not yet known. We infer from our investigations that there was evidence of multifaceted humoral antibody participation in the pathogenic events involved in renal allograft deterioration ofthe patients we have studied. The relative impact of two kinds of antibody systems (cytotoxic and antitissue antibodies), contrasted to primary cellular immune mechanisms, cannot be established from our observations. The more consistent detection of cytotoxic antibodies in the eluates tested suggests that they may be the more important antibody expression of graft-directed humoral immunity. Further studies will be needed to characterize the antigens involved and to quantify the in vitro activity and pathogenic significance of antibodies that can be eluted from allografts undergoing rejection.
